Navigation Links
China Botanic Pharmaceutical Inc. Announces Withdrawal Of Request For Hearing
Date:6/7/2013

HARBIN, China, June 7, 2013 /PRNewswire/ -- China Botanic Pharmaceutical Inc. (AMEX: CBP) (formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, announced today that on June 5, 2013, the Company submitted a notice to the NYSE MKT LLC (the "Exchange") of its decision to withdraw its appeal of the Staff's determination to delist the Company's securities from the NYSE MKT. As a result, the Company has been informed that the Company's common stock will be suspended from trading and the Exchange will proceed to file a Form 25 with the Securities and Exchange Commission to delist the Company's common stock from the Exchange.

As previously announced on May 2, 2012, the Company received a notice ("Delisting Notice") from the NYSE MKT LLC ("Exchange") indicating that based on the Company's noncompliance with its compliance plan previously submitted by the Company on February 7, 2013 to regain compliance with Sections 134 and 1101 of the NYSE MKT Company Guide ("Company Guide") by May 1, 2013 (the "Compliance Plan"), the Exchange has made a determination to delist the common stock of the Company from the Exchange. The Delisting Notice indicated that under Sections 1203 and 1009(d) of the Company Guide, the Company has a limited right to appeal the Exchange's determination by requesting an oral hearing or a hearing based on a written submission before the Exchange's Listing Qualifications Panel ("Panel"). On May 9, 2013, the Company submitted a request for a  hearing and paid the applicable hearing fee, and an oral hearing date was set for June 28, 2013. However, based on the progress of its audit, the Company has decided to not appeal by withdrawing its request for hearing. As a result of the Company's decision not to appeal, the Company has been informed that the delisting determination is final and the Exchange will proceed to file an application with the Securities and Exchange Commission to delist the Company's common stock from the Exchange.

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.

China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

Company Contact:

China Botanic Pharmaceutical Inc.

Ms. Portia Tan, IR Contact

Tel: 86-451-8260-2162

Email: ir@renhuang.com

 

 


'/>"/>
SOURCE China Botanic Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OrthoTec China 2013 is Coming Up Soon
2. China Biologic Updates the Hong Kong Litigation in respect of the Shares Held by Ms. Siu Ling Chan
3. China & North East Asia Medical Device Market Reports
4. iBio Obtains New IP Protection in China
5. China Nepstar Chain Drugstore Ltd. Reports First Quarter 2013 Financial Results
6. China Nepstar Chain Drugstore Ltd. Announces Appointment of New Director
7. China Biologic Comments on the Proposed Shanghai RAAS Transaction
8. Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
9. China Pharmaceutical Market Guidebook Series (4) 2013 Report
10. Hemp, Inc. Signs Letter of Intent with One of Chinas Largest Agricultural Producers, Yasheng Group
11. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... , May 30, 2016 ... H1 2016" market research report with comprehensive information ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:5/27/2016)... 2016 According to the 2016 ... driving ambulatory blood pressure monitoring system market growth. With ... ability to respond to different pressure rates, leading to ... to various cardiovascular disorders such as heart failure, stroke, ... are growing in prevalence each year. WHO estimates that ...
(Date:5/27/2016)... , May 27, 2016 The ... manufacturers, health insurance companies all falling under its umbrella.  ... companies. While not often talked about, these healthcare companies ... United States is by far the largest ... Medical Isotope Corp. (OTC: ADMD), Nutranomics Inc. (OTC: NNRX), ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices ... But this approach has proven transformative, both for people who hear voices and for ... is used around the world, but it still lags in the United States. , ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... commercial molecular diagnostics device that enables unprecedented portability and convenience. , The Cube ... four inches cubed in size, the Cube fits easily into any space, whether ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... WaterField ... for digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ... waxed canvas or ballistic nylon, the Duo is smartly designed for Dad’s ...
(Date:5/31/2016)... ... , ... Phynd Technologies, Inc. announced recently the signing of three new hospitals: ... Medical Center – Somers Point, NJ. The new clients range in bed size from ... of Phynd’s solution and its interoperability. , Houston Methodist is a leading academic medical ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... firm and statement solutions provider, for the tenth consecutive year as a ... issue of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing ...
Breaking Medicine News(10 mins):